115 related articles for article (PubMed ID: 38382225)
21. A comparative study of three ternary complexes prepared in different mixing orders of siRNA/redox-responsive hyperbranched poly (amido amine)/hyaluronic acid.
Chen CJ; Zhao ZX; Wang JC; Zhao EY; Gao LY; Zhou SF; Liu XY; Lu WL; Zhang Q
Int J Nanomedicine; 2012; 7():3837-49. PubMed ID: 22888238
[TBL] [Abstract][Full Text] [Related]
22. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression.
Masjedi A; Ahmadi A; Atyabi F; Farhadi S; Irandoust M; Khazaei-Poul Y; Ghasemi Chaleshtari M; Edalati Fathabad M; Baghaei M; Haghnavaz N; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Sabz G; Hasanzadeh S; Jadidi-Niaragh F
Int J Biol Macromol; 2020 Apr; 149():487-500. PubMed ID: 32004600
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
24. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
25. Dual-targeted delivery system using hollow silica nanoparticles with H
Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892
[TBL] [Abstract][Full Text] [Related]
26. Bioreducible Cross-Linked Hyaluronic Acid/Calcium Phosphate Hybrid Nanoparticles for Specific Delivery of siRNA in Melanoma Tumor Therapy.
Zhou Z; Li H; Wang K; Guo Q; Li C; Jiang H; Hu Y; Oupicky D; Sun M
ACS Appl Mater Interfaces; 2017 May; 9(17):14576-14589. PubMed ID: 28393529
[TBL] [Abstract][Full Text] [Related]
27. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
29. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.
Ganesh S; Iyer AK; Gattacceca F; Morrissey DV; Amiji MM
J Control Release; 2013 Dec; 172(3):699-706. PubMed ID: 24161254
[TBL] [Abstract][Full Text] [Related]
30. Delivery of siRNA using hyaluronic acid-guided nanoparticles for downregulation of CXCR4.
Çağdaş Tunalı B; Çelik E; Budak Yıldıran FA; Türk M
Biopolymers; 2023 Apr; 114(4):e23535. PubMed ID: 36972328
[TBL] [Abstract][Full Text] [Related]
31. Redox-responsive waterborne polyurethane nanocarriers for targeted doxorubicin delivery.
Mahdieh A; Motasadizadeh H; Yeganeh H; Nyström B; Dinarvand R
Int J Pharm; 2022 Nov; 628():122275. PubMed ID: 36265661
[TBL] [Abstract][Full Text] [Related]
32. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs.
Kim EJ; Shim G; Kim K; Kwon IC; Oh YK; Shim CK
J Gene Med; 2009 Sep; 11(9):791-803. PubMed ID: 19569085
[TBL] [Abstract][Full Text] [Related]
33. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting.
Yoon HY; Kim HR; Saravanakumar G; Heo R; Chae SY; Um W; Kim K; Kwon IC; Lee JY; Lee DS; Park JC; Park JH
J Control Release; 2013 Dec; 172(3):653-61. PubMed ID: 24055507
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal Macrophage-Specific TNF-α Gene Silencing in LPS-Induced Acute Inflammation Model Using CD44 Targeting Hyaluronic Acid Nanoparticles.
Kosovrasti VY; Nechev LV; Amiji MM
Mol Pharm; 2016 Oct; 13(10):3404-3416. PubMed ID: 27552547
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.
Song S; Qi H; Xu J; Guo P; Chen F; Li F; Yang X; Sheng N; Wu Y; Pan W
Pharm Res; 2014 Nov; 31(11):2988-3005. PubMed ID: 24842660
[TBL] [Abstract][Full Text] [Related]
36. Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review.
Salari N; Mansouri K; Valipour E; Abam F; Jaymand M; Rasoulpoor S; Dokaneheifard S; Mohammadi M
Daru; 2021 Dec; 29(2):439-447. PubMed ID: 34499323
[TBL] [Abstract][Full Text] [Related]
37. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
38. Fine Tuning of Core-Shell Structure of Hyaluronic Acid/Cell-Penetrating Peptides/siRNA Nanoparticles for Enhanced Gene Delivery to Macrophages in Antiatherosclerotic Therapy.
Zhao Y; He Z; Gao H; Tang H; He J; Guo Q; Zhang W; Liu J
Biomacromolecules; 2018 Jul; 19(7):2944-2956. PubMed ID: 29641895
[TBL] [Abstract][Full Text] [Related]
39. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD
Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572
[TBL] [Abstract][Full Text] [Related]
40. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
